$DOCS

Yang Watkin Phoebe L. sold $34K of DOCS

Yang Watkin Phoebe L. sold 1,290 shares of Doximity, Inc. (DOCS) at $26.71 on 2026-09-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yang Watkin Phoebe L.
Published Oct 2, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
medium confidence
Mentioned
$DOCS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but may be noted by short‑term traders.

02

Market read

A routine insider sale with limited market impact; primarily of interest to insiders‑focused traders.

03

What to watch

Potential upcoming earnings or product announcements could outweigh the modest insider sell.

Relevance 2/10Novelty 2/10Timing: filing today

Background

Doximity (DOCS) is a professional network for physicians; insider transactions are monitored for signals.

Company-level read

Ticker impact

$DOCSNeutralMedium confidence
Context

Director Yang Watkin Phoebe L. sold 1,290 shares for $34,456 via a 10b5‑1 plan, reducing her holding to 24,744 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

Form 4 filing is a primary source but the transaction size is small relative to market cap, limiting material impact.

Market effects

Minimal effect on the broader health‑tech sector.

No significant regional impact.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine portfolio rebalancing and not indicative of negative outlook.

Key entities

  • Yang Watkin Phoebe L.

    Director of Doximity who executed the sale under a pre‑arranged 10b5‑1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.